Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Elite One acquires Nutritional Labs International
Elite One, a holding company majority-owned by Ampersand Capital Partners, a middle-market growth equity firm with a track record of success operating and growing leading manufacturing businesses in
Elite One, a holding company majority-owned by Ampersand Capital Partners, a middle-market growth equity firm with a track record of success operating and growing leading manufacturing businesses in
Axxess Pharma anticipates Canadian pharmacies expanding the TapouT line of products on their shelves. The expansion is anticipated to include TapouT supplement and protein categories, such as TapouT
Interim data indicates that in all nine of the BMN 190 patients who have been followed for at least six months and up to 15 months, the treatment
The research agreement will identify targets for this therapy in myelodysplastic syndrome (MDS), a bone marrow disorder in which the body does not produce sufficient healthy blood cells.
DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube. DUOPA
"Sparsentan has the potential to be a significant medicine, and could transform the treatment of FSGS," said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. "The
This new agreement includes a cross-license of intellectual property (IP) on four disease targets, providing each company with exclusive RNA therapeutic license rights for two programs. The agreement
The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases. Under
Under this agreement, Fast Forward will provide funding to Bionure for the late-preclinical development of BN201 to enable IND filling to support the Phase 1 clinical study in
The patent broadly and specifically covers the company’s dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans,